▎WuXiEdited by Kant Content Team

Bristol Myers Squibb Company recently announced itsResults of the Phase 3 Clinical Trial KRYSTAL-12 for the KRAS G12C Inhibitor Krazati (adagrasib). This study evaluated Krazati in locally advanced or metastaticKRAS Efficacy in patients with G12C-mutant non-small cell lung cancer (NSCLC). These patients had previously received platinum-based chemotherapy and concurrently or sequentially underwent anti-PD-1/PD-L1 therapy.

Krazati also demonstrated a significant intracranial response rate in patients with central nervous system (CNS) metastases at baseline, with a BICR-assessed response rate of 24%, more than double that of the chemotherapy group (11%).The KRYSTAL-12 study is still ongoing to evaluate the key secondary endpoint of overall survival.

No new safety signals were identified for Krazati, and the safety data were consistent with the known safety profile. Among patients receiving Krazati, 94% reported treatment-related adverse events (TRAEs) of any grade, compared to 86.4% of those receiving chemotherapy. The incidence of TRAEs of Grade 3 or higher was 47% and 46%, respectively.

Krazati is a highly specific and potent oral KRAS G12C inhibitor, optimized for sustained target inhibition.Krazati has a half-life of up to 24 hours and extensive tissue distribution, and it is also able to cross the blood-brain barrier, which helps maximize drug efficacy. In June 2021, the FDA granted it Breakthrough Therapy designation, and it was approved by the FDA for marketing in December 2022 for the treatment of patients carryingKRAS G12CPatients with mutated, previously treated non-small cell lung cancer. Zai Lab has obtained the rights for research, development, production, and exclusive commercialization of this therapy in Greater China.Except forKRAS In addition to NSCLC with G12C mutations, Krazati and its combination therapies have shown encouraging and meaningful efficacy across various tumors in phase 2 clinical trials, including advanced colorectal cancer, pancreatic cancer, and other solid tumors.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the WuXi AppTec content team. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.